type
1
description
summary
冯宇雄 博士
浙江大学“****”研究员 博士生导师
浙江大学转化医学研究院 研究员
浙江大学医学院附属第一医院 双聘教授浙江省领军型创新创业团队 核心成员
工作单位：浙江大学转化医学研究院
2004-2010 中科院上海生命科学研究院，生物化学与分子生物学专业，博士2000-2004浙江大学生命科学学院，生物技术专业，本科
研究经历2018-现 浙江大学转化医学研究院\/浙江大学附属第一医院，研究员\/博士生导师2010-2017 麻省理工学院\/Whitehead生物医学研究所，博士后
1. Feng M, Jin JQ, Xia L, et al., Feng YX*, Zhu D*. 2019. Pharmacological inhibition of β-catenin\/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Science Advances 08 May 2019: Vol. 5, no. 5 (*co-corresponding author)
2. Feng YX, Jin DX, Sokol ES, Reinhardt F, Miller DH, Gupta PB. 2017. Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1. Nature Communications 8:1079
3. Sokol ES*, Feng YX*, Jin DX*, Tizabi MD, Miller DH, et al. 2017. SMARCE1 is required for the invasive progression of in situ cancers. PNAS 114:4153-8 (*co-first author)
4.Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al. 2014. Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discovery 4:702-15
5.Feng YX, Sokol ES, Gupta PB. 2014. The endoplasmic reticulum may be an Achilles' heel of cancer cells that have undergone an epithelial-to-mesenchymal transition. Molecular & Cellular Oncology 1:e961822
6.Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al. 2011. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53:483-92
7.Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, et al. 2010. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1\/Akt\/NF-kappaB signaling pathway. Hepatology 51:535-44
已获专利
“ER-stress inducing compounds and methods of use thereof”, United States Patent **
template_id
1
photo
research_field
status
1
opendate
2018-03-31 17:41:39
access_type
1
access_count
7868
score
connect
selfintroduction
url
telephone
yxfeng@zju.edu.cn
address
江干区凯旋路268号华家池校区中心大楼北楼209室
research
mypage_id
work_title
learn_degree
work_post
research_orientation
handle
c630fbc934c711ea53c1c
main_status
1
access_uid_status
1
theme_id
qrcode_status
1
gmt_qrcode
2021-01-22 09:24:51
content
冯宇雄 博士
浙江大学“****”研究员 博士生导师
浙江大学转化医学研究院 研究员
浙江大学医学院附属第一医院 双聘教授浙江省领军型创新创业团队 核心成员
工作单位：浙江大学转化医学研究院
2004-2010 中科院上海生命科学研究院，生物化学与分子生物学专业，博士2000-2004浙江大学生命科学学院，生物技术专业，本科
研究经历2018-现 浙江大学转化医学研究院\/浙江大学附属第一医院，研究员\/博士生导师2010-2017 麻省理工学院\/Whitehead生物医学研究所，博士后
1. Feng M, Jin JQ, Xia L, et al., Feng YX*, Zhu D*. 2019. Pharmacological inhibition of β-catenin\/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Science Advances 08 May 2019: Vol. 5, no. 5 (*co-corresponding author)
2. Feng YX, Jin DX, Sokol ES, Reinhardt F, Miller DH, Gupta PB. 2017. Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1. Nature Communications 8:1079
3. Sokol ES*, Feng YX*, Jin DX*, Tizabi MD, Miller DH, et al. 2017. SMARCE1 is required for the invasive progression of in situ cancers. PNAS 114:4153-8 (*co-first author)
4.Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al. 2014. Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discovery 4:702-15
5.Feng YX, Sokol ES, Gupta PB. 2014. The endoplasmic reticulum may be an Achilles' heel of cancer cells that have undergone an epithelial-to-mesenchymal transition. Molecular & Cellular Oncology 1:e961822
6.Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al. 2011. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53:483-92
7.Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, et al. 2010. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1\/Akt\/NF-kappaB signaling pathway. Hepatology 51:535-44
已获专利
“ER-stress inducing compounds and methods of use thereof”, United States Patent **
column_name
个人简介
